multiple myeloma

At the 52nd annual meeting of the American Society of Hematology, which wraps up Tuesday, Novartis, Celgene and Seattle Genetics revealed the latest news from their studies on blood diseases and cancers. But despite some positive results, all three had down days in the stock market.

Onyx Pharmaceuticals (ONXX) announced what it called "promising results" from a mid-stage study of its experimental drug carfilzomib in patients with relapsed and refractory multiple myeloma. ONXX shares soared 12% in recent premarket activity. Patients in the trial had been previously treated, but...

There must be holiday cheer in the executive suite at biotech Celgene (CELG), where the stock is up 15% over last year. The Summit, N.J.-based company's cancer pill Revlimid generated $1.3 billion in sales last year. And it did so as a backup therapy for patients with the blood cancer multiple...